12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LL-37: Preliminary Phase II data

Preliminary data from a double-blind, Swedish Phase I/II trial in 34 patients with venous leg ulcers showed that LL-37 for 1 month was well tolerated at the 0.5 and 1.6 mg/mL doses,...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >